Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

(2018) Andrew Blauvelt et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies

(2018) Jorge R. Georgakopoulos et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab

(2018) Giovanni Damiani et al.   Dermatologic Therapy

Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis

(2015) L. E. Durham et al.   Current Rheumatology Reports

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

(2012) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Definition of treatment goals for moderate to severe psoriasis: a European consensus

(2010) U. Mrowietz et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH